Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28632594 | 0.98 | CA1 (0.40) | CA1CA2HDAC3PARP1HSD17B3 | |
| SCHEMBL1389215 | 0.81 | HDAC3 (0.38) | CA1CA2HDAC3PARP1HSD17B3 | |
| SCHEMBL28319871 | 0.75 | SIGMAR1 (0.32) | — | |
| SCHEMBL9400605 | 0.73 | CA1 (0.38) | CA1CA2HDAC3PARP1HSD17B3 | |
| SCHEMBL28526384 | 0.73 | HDAC3 (0.45) | CA1CA2HDAC3PARP1HSD17B3 | |
| SCHEMBL3069885 | 0.73 | HDAC3 (0.43) | CA1CA2HDAC3PARP1HSD17B3 | |
| SCHEMBL143063 | 0.69 | HDAC3 (0.38) | CA1CA2HDAC3PARP1HSD17B3 | |
| SCHEMBL1564351 | 0.69 | HDAC3 (0.41) | CA1CA2HDAC3PARP1HSD17B3 | |
| SCHEMBL13932579 | 0.69 | HDAC3 (0.38) | CA1CA2HDAC3PARP1HSD17B3 | |
| SCHEMBL11353696 | 0.69 | HDAC3 (0.38) | CA1CA2HDAC3PARP1HSD17B3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110256342-B | Synthetic method of 2-cyano quinoline derivative | 河南省科学院化学研究所有限公司 | 2022-06-07 | — | — | CN | disclosed |
| CN-110256342-A | A kind of synthetic method of 2- cyano-quinoline derivatives | 河南省科学院化学研究所有限公司 | 2019-09-20 | — | — | CN | disclosed |
| WO-2019111218-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS IRAK4 INHIBITORS | CADILA HEALTHCARE LIMITED (IN) | 2019-06-13 | — | — | WO | disclosed |
| CN-107921032-A | Inhibitors of VMAT2 for use in treating neurological diseases or disorders | 纽罗克里生物科学有限公司 | 2018-04-17 | — | — | CN | disclosed |
| CN-107438606-A | [9,10 dimethoxy 3 (2 methyl-propyl) 1H, 2H, 3H, 4H, 6H, 7H, the base of 11BH pyridos [2,1 A] isoquinolin 2] methanol and relative compound, composition and method | 纽罗克里生物科学有限公司 | 2017-12-05 | — | — | CN | disclosed |
| CN-106459071-A | New tricyclic quinone derivative | 波士顿生物技术公司 | 2017-02-22 | — | — | CN | disclosed |
| CN-106061506-A | Pharmaceutical compositions comprising an antipsychotic agent and a VMAT2 inhibitor and uses thereof | 纽罗克里生物科学有限公司 | 2016-10-26 | — | — | CN | disclosed |
| EP-2718291-A1 | BENZOQUINOLIZIDINE DERIVATIVES, METHOD FOR PREPARING SAME, AND THERAPEUTIC USES THEREOF | Pierre Fabre Medicament (FR) | 2014-04-16 | — | — | EP | disclosed |
| WO-2012168368-A1 | BENZOQUINOLIZIDINE DERIVATIVES, METHOD FOR PREPARING SAME, AND THERAPEUTIC USES THEREOF | PIERRE FABRE MEDICAMENT (FR) | 2012-12-13 | — | — | WO | disclosed |
| US-8148443-B2 | Oxonium and sulfonium salts | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-04-03 | — | — | US | disclosed |
| US-20110034698-A1 | Oxonium And Sulfonium Salts | IGNATYEV NIKOLAI MYKOLA | 2011-02-10 | — | — | US | disclosed |
| EP-2271643-A1 | COMPOUNDS | Glaxo Group Limited (GB) | 2011-01-12 | — | — | EP | disclosed |
| US-7842804-B2 | Ionic salts comprising pyrrolidinium, triazolinium, piperidinium or morpholinium cations and alkyltrifluorophosphate anions | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-11-30 | — | — | US | disclosed |
| WO-2009133136-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-11-05 | — | — | WO | disclosed |
| CN-101379070-A | Oxonium and sulfonium salts | MERCK PATENT GMBH (DE) | 2009-03-04 | — | — | CN | disclosed |
| US-20090036628-A1 | OXONIUM AND SULFONIUM SALTS | MERCK PATENT GESELLSCHAFT (DE) | 2009-02-05 | — | — | US | disclosed |
| EP-1355886-A1 | FUSED HETEROCYCLIC COMPOUNDS | Takeda Chemical Industries, Ltd. (JP) | 2003-10-29 | — | — | EP | disclosed |
| WO-2002062764-A9 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2002-10-10 | — | — | WO | disclosed |
| WO-2002062764-A1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034698-A1 | Oxonium And Sulfonium Salts | PRDX2, SCO2, SFXN1 | CA1 2511/4885CA2 939/4885HDAC3 3477/4885 |
| US-20090036628-A1 | OXONIUM AND SULFONIUM SALTS | SCO2, PRDX2, SFXN1 | CA1 2491/4885CA2 992/4885HDAC3 3193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.